Cancer vaccine developer secures £12.8m

GBP pound sterling funding

Oxford University spin-out Infinitopes Precision Immunomics has completed a £12.8 ($16) million seed funding round led by Octopus Ventures.

The round was heavily oversubscribed, also drawing in funds from Cancer Research Horizons, Cancer Research Institute, CRIS Cancer Foundation, Kindred Capital, Manta Ray, Martlet Capital, Meltwind Advisory, Saras Capital, Wilbe Capital, and expert angel investors.

The total funds raised combine new equity investment and a prestigious non-dilutive award from Innovate UK’s Future Economy Investor Partnership scheme.

Jonathan Kwok, CEO and Co-founder of Infinitopes, said: “Our therapies are emerging at a time when blockbuster checkpoint inhibitors are hitting their peak, capable of preventing tumour recurrence in 30-40% of patients at best. Our preclinical results suggest that our vaccines may significantly outperform them, to transform care for future cancer patients.”

The new investment will enhance the company’s tumour antigen discovery and computational immunobiology/AI/machine learning techniques, to identify and rank the best target combinations, to treat five more cancers.

It will also support development of Infinitopes’ lead asset, a novel cancer vaccine called ITOP1, which is scheduled to commence a Phase I/IIa study in first line cancer patients in the third quarter of 2024.

Phil Masterson, Associate Director, Cancer Research Horizons, commented: “Infinitopes is at the forefront of the cancer vaccine revolution emerging from Covid-era technology advances. Cancer Research Horizons’ investment strategy focuses on maximising patient impact – Infinitopes is empowering the immune system to fight the cancer metastases that cause 70-90% of cancer deaths through better targeting, better delivery mechanisms and better clinical trials.  We are delighted to support the building of a leading company based on innovative CRUK-funded foundational science.”

Diana Spencer, Senior Digital Content Editor, DDW

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free